image
Healthcare - Biotechnology - NASDAQ - US
$ 1.45
-0.685 %
$ 8.07 M
Market Cap
-0.05
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one TRAW stock under the worst case scenario is HIDDEN Compared to the current market price of 1.45 USD, Traws Pharma, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one TRAW stock under the base case scenario is HIDDEN Compared to the current market price of 1.45 USD, Traws Pharma, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one TRAW stock under the best case scenario is HIDDEN Compared to the current market price of 1.45 USD, Traws Pharma, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TRAW

image
$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.0$5.0$5.0$4.0$4.0$3.0$3.0$2.0$2.0$1.0$1.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
226 K REVENUE
0.00%
-142 M OPERATING INCOME
-601.42%
-167 M NET INCOME
-778.84%
-29.8 M OPERATING CASH FLOW
-66.14%
-3.65 M INVESTING CASH FLOW
-25957.14%
34 M FINANCING CASH FLOW
0.00%
57 K REVENUE
1.79%
-5.2 M OPERATING INCOME
1.42%
21.5 M NET INCOME
171.82%
-5.44 M OPERATING CASH FLOW
-34.58%
0 INVESTING CASH FLOW
0.00%
13 K FINANCING CASH FLOW
-99.93%
Balance Sheet Traws Pharma, Inc.
image
Current Assets 25 M
Cash & Short-Term Investments 21.3 M
Receivables 1.76 M
Other Current Assets 1.85 M
Non-Current Assets 11 K
Long-Term Investments 0
PP&E 10 K
Other Non-Current Assets 1 K
85.48 %7.07 %7.40 %Total Assets$25.0m
Current Liabilities 11.5 M
Accounts Payable 8.19 M
Short-Term Debt 0
Other Current Liabilities 3.35 M
Non-Current Liabilities 45.1 M
Long-Term Debt 0
Other Non-Current Liabilities 45.1 M
14.46 %5.91 %79.62 %Total Liabilities$56.6m
EFFICIENCY
Earnings Waterfall Traws Pharma, Inc.
image
Revenue 226 K
Cost Of Revenue 12 K
Gross Profit 214 K
Operating Expenses 143 M
Operating Income -142 M
Other Expenses 24.1 M
Net Income -167 M
20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)(180m)(180m)226k(12k)214k(143m)(142m)(24m)(167m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
94.69% GROSS MARGIN
94.69%
-62997.35% OPERATING MARGIN
-62997.35%
-73682.74% NET MARGIN
-73682.74%
526.47% ROE
526.47%
-667.11% ROA
-667.11%
-1060.20% ROIC
-1060.20%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Traws Pharma, Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -167 M
Depreciation & Amortization 12 K
Capital Expenditures 0
Stock-Based Compensation 1.39 M
Change in Working Capital -6.57 M
Others 136 M
Free Cash Flow -29.8 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Traws Pharma, Inc.
image
TRAW has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Traws Pharma, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
5.18 M USD 4
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southern Hemisphere globenewswire.com - 1 week ago
Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib NEWTOWN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the publication of key clinical efficacy data for rigosertib, a legacy Traws Pharma oncology asset for which development and commercialization partners are being actively sought, in patients with RDEB SCC. The paper, published in the British Journal of Dermatology 1 , details the first clinical trial of any experimental cancer therapeutic in this rare and complicated monogenic disease. The results indicated an overall response rate of 80%, with complete responses in 50% of evaluable patients. globenewswire.com - 1 month ago
Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness NEWTOWN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced receipt of written responses to questions submitted for a Type B pre-Investigational New Drug Application meeting with the U.S. Food and Drug Administration (FDA, the Agency). The FDA provided feedback on development paths for potential approval of tivoxavir marboxil (TXM) for bird flu and seasonal flu, including on the use of the Animal Rule. The Animal Rule is intended to provide a path to approval in situations when human clinical studies would be unethical or impractical. globenewswire.com - 1 month ago
Traws Pharma Reports First Quarter 2025 Results and Business Highlights FDA briefing document submitted April 24, 2025 in support of a meeting to align on pathway for tivoxavir marboxil (TXM, bird flu/seasonal flu) including potential for accelerated approval utilizing the “Animal Rule” globenewswire.com - 1 month ago
Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript Traws Pharma, Inc. (NASDAQ:TRAW ) Virtual Investor Event March 31, 2025 10:00 AM ET Company Participants Werner Cautreels – Chief Executive Officer Robert Redfield – Chief Medical Officer David Pauza – Chief Science Officer-Virology Iain Dukes – Executive Chairman Bruce Mackle – LifeSci Advisors Conference Call Participants Operator Good morning, and welcome to the Traws Pharma Investor Call on Bird Flu and COVID and Traws Innovative Small Molecule Product Candidates. At this time all attendees are in a listen-only mode. seekingalpha.com - 3 months ago
Traws Pharma Announces Management Updates NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the retirement of Werner Cautreels, PhD, Chief Executive Officer (CEO), effective on or about close of business on March 31, 2025 after the Company files its Annual Report on Form 10-K with the Securities and Exchange Commission. Iain D. Dukes, D Phil, will assume the role of Interim CEO. In addition to his new responsibilities, Dr. Dukes will continue to serve as Traws' Chairman. globenewswire.com - 3 months ago
Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET Event to highlight the differentiated features of Traws oral small molecule product candidates: Tivoxavir Marboxil, a single dose, CAP-dependent endonuclease inhibitor for Bird Flu Ratutrelvir, a main protease inhibitor, to be used without ritonavir, for COVID-19 NEWTON, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced that it will host a virtual investor event on Monday, March 31, 2025 at 10:00 AM ET. globenewswire.com - 3 months ago
Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR NEWTOWN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced that positive data supporting the potential for ratutrelvir, a main protease inhibitor, as a treatment for COVID-19, were presented on March 20, 2025 in a poster at the International Conference for Antiviral Research (ICAR 2025), held in Las Vegas, Nevada. globenewswire.com - 3 months ago
Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR NEWTOWN, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced that positive data supporting the potential for tivoxavir marboxil (TXM) as a bird flu treatment was presented yesterday in a poster at the International Society for Antiviral Research (ICAR 2025), being held in Las Vegas, Nevada. globenewswire.com - 3 months ago
Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil NEWTOWN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of respiratory viral diseases, today announced positive topline results from ferrets infected with H5N1 bird flu, an accepted animal model for human influenza, when treated with tivoxavir marboxil as a single dose. These data are consistent with results reported in December 2024 in a murine model. The new studies reported today evaluated the efficacy of a single dose of tivoxavir marboxil as a treatment for bird flu isolated from a Texas dairy worker and showed suppression of disease, with reduced viral burden in lungs. globenewswire.com - 4 months ago
Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule NEWTOWN, Pa., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW) (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for the treatment of respiratory viral diseases, announced today that it has received confirmation from Nasdaq that Traws has regained compliance with the minimum stockholders' equity requirements of Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain a minimum of $2.5 million in stockholders' equity. Accordingly, Traws common stock will continue to be listed and trade on The NASDAQ Capital Market under the symbol “TRAW”. globenewswire.com - 4 months ago
Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu Phase I completed in healthy volunteers with pharmacokinetic data supporting dosing for both therapeutic and further development for bird flu prevention NEWTOWN, Pa. , Jan. 23, 2025 /PRNewswire/ -- Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of respiratory viral diseases, today announced completion of Phase I clinical studies of its investigational one-dose influenza (flu) therapy, tivoxavir marboxil (tivoxavir), for the treatment or prevention of H5N1 bird flu. prnewswire.com - 5 months ago
8. Profile Summary

Traws Pharma, Inc. TRAW

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 8.07 M
Dividend Yield 0.00%
Description Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Contact 12 Penns Trail, Newtown, PA, 18940 https://www.trawspharma.com
IPO Date None
Employees 6
Officers Dr. Robert R. Redfield M.D. Chief Medical Officer Dr. Victor Moyo M.D. Chief Medical Officer of Oncology Dr. Iain D. Dukes DPHIL, M.A., Ph.D. Interim Chief Executive Officer, Secretary & Director Ms. Nora E. Brennan Interim Chief Financial Officer Dr. Nikolay Savchuk Ph.D. Chief Operating Officer & Director Dr. Charles David Pauza Ph.D. Chief Scientific Officer of Virology